Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,484.02 66.49 0.46%
TOPIX 1,169.43 2.84 0.24%
HANG SENG 22,760.24 64.23 0.28%

Phase I Data Evaluating Safety, Tolerability and Pharmacokinetics of Multiple Weekly Doses of Dalbavancin Presented at the 23rd



Phase I Data Evaluating Safety, Tolerability and Pharmacokinetics of Multiple
Weekly Doses of Dalbavancin Presented at the 23rd Annual ECCMID Meeting

Achieves Steady-State With No Observable Accumulation After 8 Weeks of Dosing

CHICAGO, April 29, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc.
(Nasdaq:DRTX) today announced data from a Phase 1 study of its lead product
candidate, dalbavancin, under investigation for the treatment of susceptible
gram positive bacterial infections including MRSA. The data, presented at the
23^rd Annual European Congress of Clinical Microbiology and Infectious
Diseases (ECCMID), demonstrate that dalbavancin, when administered to healthy
subjects as an IV infusion weekly for a total of up to 8 weeks, was well
tolerated.

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple
Weekly Doses of Intravenous Dalbavancin in Healthy Subjects Authors: M. Dunne,
C. Sprenger, S. Moriarty (Branford, US) Poster #: P910

Study conclusions: Dalbavancin was well-tolerated when administered IV as a
loading dose of 1000 mg followed by 500 mg weekly for a total of up to 8
weeks. With a loading dose of 1000mg on Day 1, the 500 mg weekly dose achieves
steady-state by Day 8 with no observable accumulation. This dosing regimen of
dalbavancin should be considered for further study in clinical indications
which require longer duration of therapy, such as osteomylelitis.

Further Study Details

This was a single center, open-label, multiple-dose, safety, tolerability, and
PK study of increasing dosing durations. The total sample size for this study
was 18 subjects, divided into 3 dosing cohorts of 6 subjects each. All
subjects were asymptomatic, non-smoking adult volunteers between the ages of
18 and 55. All subjects received 1000 mg IV on Day 1. Cohort 1 received
subsequent 500 mg IV doses on Days 8, 15 and 22; Cohorts 2 received additional
500 mg IV doses on Days 29 and 36; and Cohort 3 received additional 500 mg
doses on Days 43 and 50. Drug was administered over 30 minutes. Standard
safety parameters were monitored throughout the study.

For the dalbavancin 500 mg IV dose given on the last day of dosing, the AUC
(µg·h/mL) was 10202.82, 12992.79 and 12173.30 and the C-max was 160.00, 187.00
and 179.67 in Cohorts I, II and III respectively. The calculated elimination
curve reflected the beta (β) T-1/2 of Dalbavancin of 99 to 109 hours. Steady
state was achieved by Day 9 with no observable accumulation. No serious AEs
were reported over the course of this study. The most common treatment
emergent AE reported was mild pain in the extremity, reported by 2 subjects,
without evidence of thrombophlebitis. No subject withdrew or was discontinued
from the study. No laboratory abnormality was attributed to Dalbavancin.

A copy of this poster is available on Durata's
website: www.duratatherapeutics.com. 

About Dalbavancin

Dalbavancin is an intravenous antibiotic product candidate under investigation
for once-weekly dosing, which we believe may facilitate the treatment of
patients with ABSSSI in both the in-patient and out-patient settings,
potentially reducing the length of a patient's hospital stay or avoiding
hospital admission altogether, with an impact on the overall cost of care for
these patients. 

About Durata Therapeutics

Durata Therapeutics is a pharmaceutical company focused on the development and
commercialization of novel therapeutics for patients with infectious diseases
and acute illnesses. Durata has completed two global Phase 3 clinical trials
with its lead product candidate, dalbavancin, under investigation for the
treatment of patients with acute bacterial skin and skin structure infections,
or ABSSSI.

Forward-looking Statements

Statements contained in this press release contain forward-looking statements
that involve substantial risks and uncertainties. All statements, other than
statements of historical facts, contained in this press release, including
statements regarding our strategy, future operations, future financial
position, future revenues, projected costs, prospects, plans and objectives of
management, are forward-looking statements. The words "anticipate," "believe,"
"estimate," "expect," "intend," "may," "plan," "predict," "project," "target,"
"potential," "will," "would," "could," "should," "continue," and similar
expressions are intended to identify forward-looking statements, although not
all forward-looking statements contain these identifying words.

CONTACT: Investor Relations and Public Affairs Contact
         Allison Wey
         Durata Therapeutics
         Vice President, Investor Relations and Public Affairs
         (312) 219-7017
         awey@duratatherapeutics.com
        
         Media Relations Contact
         Jed Weiner
         White Oak Communications, Inc.
         (847) 392-4186
         jed.weiner@comcast.net

Durata Therapeutics, Inc. Logo
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement